Kirin Holdings Company Limited TOKYO2503 and Kao Corporation TOKYO4452 will participate in the Wakayama Health Promotion Study a cohort study2 led by Wakayama Medical University and organized by the Health Promotion Research Center HPRC a nonprofit organization.
Kirin says that revenue from LC-Plasma, its flagship immune health ingredient, has grown significantly even during spring and summer this year, although these are seasons when consumers tend to take fewer precautions against infectious diseases.
Nagasaki University presented the results of a specified clinical trial on patients with COVID-19 using Lactococcus. lactis strain Plasma 1 , researched and developed by Kirin Holdings Company,. | May 11, 2023